August 8, 2019
Call for Entries: Deadline Extended - Submit Your Original Art Depicting Life with hATTR A ...
“The Art of Living with hATTR Amyloidosis” is a new initiative inviting members of the hereditary ATTR (hATTR) amyloidosis community – including patients...
Read More ›
June 24, 2019
Alnylam Honored by NORD with a Rare Impact Award
Alnylam Honored by NORD with a Rare Impact Award for the development and approval of ONPATTRO (patisiran).
Read More ›
June 21, 2019
Alnylam Launches PH1 of a Kind - An Animated Video Series for Kids with PH1
Yesterday, at the OHF International Hyperoxaluria Workshop in Boston, Alnylam previewed PH1 of a Kind, a new animated video series for children about living...
Read More ›
June 11, 2019
Pride 2019 - Alnylam Celebrates Diversity at Boston Pride Parade
This past Saturday, Alnylam joined approximately 750,000 people gathered in Boston for the 2019 Boston Pride Parade to honor the 50th anniversary of the...
Read More ›
June 10, 2019
Alnylam Named a Best Workplace in Switzerland & UK
Alnylam's offices in Maidenhead, UK and Zug, Switzerland were both recently named to Great Place to Work's Best Workplaces for 2019.
Read More ›
April 11, 2019
Letter to the Editor: Federal Research is Important, but Companies Turn it Into Actual Tre ...
John Maraganore wrote a Letter to the Editor in The Washington Post about the importance of federal research...
Read More ›
February 20, 2019
Alnylam Named a Fast Company World's Most Innovative Company for 2019
Alnylam has been named #3 in Biotech on Fast Company's World's 50 Most Innovative Company for 2019.
Read More ›
December 11, 2018
John Maraganore Named to Bloomberg 50 List for 2018
Alnylam CEO John Maraganore has been named to the Bloomberg 50 list for 2018.
Read More ›
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to Site